You are here

The industry’s largest antibody Fab library to date uses a unique concept for the in vitro generation of highly specific and fully human antibodies. 


which is the industry’s largest antibody Fab library to date, uses a unique concept for the in vitro generation of highly specific and fully human antibodies.

Ylanthia® goes one step further than all current antibody technologies. The technologies currently available make the successful development of therapeutic antibodies difficult in two respects. On the one hand, many antibody programs fail in later development due to inadequate biophysical properties, which classify the active ingredient as "undevelopable". If an antibody cannot be produced on a larger scale or if other properties adversely affect its handling, the chances of successful commercialization decrease. On the other hand, earlier generations of technology fail to deliver antibodies against all possible targets (epitopes) of disease-relevant target molecules. This can lead to highly promising target molecules being wrongly rejected. A lack of structural diversity, i.e. diversity, in the generation of antibodies means that not all possibilities to bind to a promising target molecule are exhausted and its role in the course of the disease is underestimated. The Ylanthia® technology has been specifically designed to remove these hurdles.

The antibody library has all the necessary prerequisites for selecting antibodies against all possible starting points of disease-relevant target molecules due to the structural range and diversity of the library. If one can succeed in exhausting all of the possibilities for binding promising target molecules, this can result in unique product opportunities and compound candidates that can intervene at the crucial points in a disease process.

Ylanthia® takes antibody technology beyond current methods. A guiding principle underlying the design and construction of the Ylanthia® library was to ensure that the library is of the highest possible quality. Features which distinguish Ylanthia® from other technologies include:

  • Size and heavy/light chain pairing: Ylanthia® is the industry’s largest known antibody Fab library, comprising over 100 billion distinct, fully human antibodies. Ylanthia® uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into unprecedented structural diversity. Great care was invested into the antigen binding site design. The library’s diversity is expected to result in antibodies against previously inaccessible target molecules and unique epitope coverage.
  • Biophysical properties: Antibody frameworks were pre-selected for expression levels, stability and aggregation behavior. A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody-products, making them more cost-effective to produce and administer. A higher solubility in turn opens up the path for more convenient formulations for patients, such as subcutaneous administration.
  • Optimization: When needed, antibodies from the Ylanthia® library are optimized using MorphoSys’s proprietary Slonomics® technology, which MorphoSys obtained through its acquisition of Sloning BioTechnology in 2010. Ylanthia® thereby distinguishes itself in a central respect from HuCAL®, which relies on a modular gene design and pre-formed cassettes for antibody optimization. Slonomics® enables optimization of Ylanthia® antibodies with unprecedented speed and flexibility.